Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Translation01:31

Translation

15.0K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
15.0K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Amyloid Fibrils03:03

Amyloid Fibrils

9.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-biological characteristics of ataxin-2 protein.

Neural regeneration research·2026
Same author

Modulation of the Stress Granule Component Carhsp1 Mitigates Disease-Associated Deficits in Spinocerebellar Ataxia Type 3 Mouse Models.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

In Vitro Antiviral Activity of Red Algae Extracts from <i>Chondracanthus teedei</i> var. <i>lusitanicus</i> and <i>Osmundea pinnatifida</i> Against Coxsackievirus A12 and a Lentiviral Vector.

Tropical medicine and infectious disease·2026
Same author

Predictive value of the hERG assay for anticipating the arrhythmogenic potential of new drugs.

Drug discovery today·2026
Same author

Molecular hallmarks of neurodegeneration in polyglutamine spinocerebellar ataxias.

Cell death & disease·2025
Same author

Insights Into Cockayne Syndrome Type B: What Underlies Its Pathogenesis?

Aging cell·2025

Related Experiment Video

Updated: Jul 18, 2025

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K

PolyQ Database-an integrated database on polyglutamine diseases.

Bernardo Estevam1,2, Carlos A Matos1,2, Clévio Nóbrega1,2

  • 1ABC-Ri, Algarve Biomedical Center Research Institute, Campus de Gambelas, Faro 8005-139, Portugal.

Database : the Journal of Biological Databases and Curation
|August 21, 2023
PubMed
Summary

Polyglutamine (polyQ) diseases are rare neurodegenerative disorders. A new free online database centralizes information on all nine polyQ diseases, aiding researchers and patients.

More Related Videos

Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

13.6K
Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

12.1K

Related Experiment Videos

Last Updated: Jul 18, 2025

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K
Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

13.6K
Assays for the Degradation of Misfolded Proteins in Cells
10:56

Assays for the Degradation of Misfolded Proteins in Cells

Published on: August 28, 2016

12.1K

Area of Science:

  • Neurogenetics
  • Molecular Biology
  • Rare Diseases

Background:

  • Polyglutamine (polyQ) diseases are a group of nine rare, monogenic neurodegenerative disorders.
  • These conditions result from expanded Cytosine, Adenine, Guanine (CAG) triplet repeats in specific genes, leading to abnormal protein structures.
  • Currently, no cures exist, and information is fragmented across various sources.

Purpose of the Study:

  • To create a centralized, free online resource for comprehensive information on all nine polyQ diseases.
  • To support researchers, clinicians, patients, and families by consolidating scattered data.

Main Methods:

  • Development of a dedicated online platform, the PolyQ Database.
  • Aggregation of information covering epidemiology, causative genes, protein characteristics, pathophysiology, and clinical manifestations.
  • Ensuring the database is continuously updated and expandable.

Main Results:

  • The PolyQ Database (https://polyq.pt/) is launched as the first platform exclusively focused on all nine polyQ diseases.
  • It provides a unified source of information relevant to diverse audiences.
  • The platform is designed for ongoing updates and information dissemination.

Conclusions:

  • The PolyQ Database addresses the critical need for centralized information on these rare neurodegenerative disorders.
  • This resource facilitates a better understanding and exploration of polyQ diseases for scientific and public benefit.
  • The database aims to be a continuously evolving hub for polyQ disease knowledge.